Proxy Results (Form 8-K)

At the Annual Meeting of stockholders (the "Annual Meeting") of Bone Biologics Corporation (the "Company"), held on September 28, 2026, the Company's stockholders voted on the matters described below. The number of shares of common stock entitled to vote at the Annual Meeting was 2,011,057. The number of shares of common stock present or represented by proxy at the Annual Meeting was 951,746. The voting results for the proposals are as follows:

Proposal 1. The Company's stockholders elected the following four director nominees to serve until the date of the next Annual Meeting of stockholders following the date such persons are elected as directors, and until their successors are duly elected and qualified. The results of the vote are summarized in the table below.

Proposal 2. The Company's stockholders approved, on an advisory basis, the Company's executive compensation. The results of the vote are summarized in the table below.

Proposal 3. The Company's stockholders ratified the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote are summarized in the table below.

Proposal 4. The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of the Company's common stock underlying certain warrants issued by us pursuant to that certain Securities Purchase Agreement, dated as of July 7, 2026, by and among the Company and the investor named on the signatory pages thereto, and that certain Engagement Letter, by and among the Company and H.C. Wainwright & Co., LLC, dated as of March 11, 2025, as amended, in an amount equal to or in excess of 20% of the Company's common stock outstanding immediately prior to the issuance of such warrants. The results of the vote are summarized in the table below.